A Case of Hyperhemolysis Syndrome in Sickle Cell Disease and Concomitant COVID-19

Hyperhemolysis syndrome (HHS) is an uncommon transfusion reaction described in several hematologic disorders, including sickle cell disease (SCD). HHS is characterized by a decline in hemoglobin (Hb) values below pre-transfusion levels following transfusion of red blood cells (RBCs), coupled with laboratory markers consistent with hemolysis. The proposed pathophysiologic mechanisms underlying HHS include increased phosphatidylserine expression, macrophage activation, and complement dysregulation.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research